Vilazodone: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
Expand Vilazodone with Stahl-sourced detail (with skepticism) |
Terminology sweep: drug/medication → medicine |
||
| Line 16: | Line 16: | ||
| intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism — similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation. | | intro = '''Vilazodone''' (brand name Viibryd) is a serotonin partial agonist reuptake inhibitor (SPARI) FDA-approved in 2011 for major depressive disorder. Combines SERT inhibition with 5HT1A receptor partial agonism — similar in spirit to buspirone-augmented SSRI therapy, but in a single molecule. Stahl positions SPARIs as a mechanistic refinement of SSRIs intended to accelerate the typical 4-6 week onset and improve tolerability via 5HT1A modulation. | ||
In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The | In practice, head-to-head trials have not consistently shown superiority over generic SSRIs. The medicine carries the typical SSRI side effect profile though sexual dysfunction may be somewhat reduced. Must be taken with food (substantial bioavailability difference). | ||
| pharmacodynamics= SERT inhibition (Ki ~0.1 nM); 5HT1A partial agonist (Ki ~0.2 nM). Minimal NET, DAT, or non-5HT1A serotonin receptor activity. | | pharmacodynamics= SERT inhibition (Ki ~0.1 nM); 5HT1A partial agonist (Ki ~0.2 nM). Minimal NET, DAT, or non-5HT1A serotonin receptor activity. | ||
| effects = Nausea, diarrhea, headache, somnolence, insomnia, vomiting. Sexual dysfunction (variably reported as similar to or less than SSRIs). SSRI discontinuation syndrome possible. Class warning for suicidal thoughts in pediatric/young adult patients. | | effects = Nausea, diarrhea, headache, somnolence, insomnia, vomiting. Sexual dysfunction (variably reported as similar to or less than SSRIs). SSRI discontinuation syndrome possible. Class warning for suicidal thoughts in pediatric/young adult patients. | ||